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effectiveness of a team-based motivational
engagement intervention to improve
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Abstract
Background: Early Intervention in Psychosis (EIP) services improve health outcomes for young people with
psychosis in the medium-long term, but 25% of young people disengage in the first 12 months with costs to their
mental health, families, society and health services. This study will evaluate the effectiveness of a team-based
motivational engagement intervention, the Early Youth Engagement (EYE-2) intervention.
Methods and design: The EYE-2 trial is a cluster randomised controlled trial comparing the EYE-2 intervention plus
standardised EIP service to standardised EIP service alone, with randomisation at the clinical team (cluster) level. The
study aimed to enrol 950 young people (aged 14–35 years) with first episode psychosis in 10 teams per arm.
Results: The primary outcome is time to disengagement: days from the date of allocation to care coordinator to
date of the last contact following either refusal to engage with an EIP team or lack of response to EIP contact for 3
consecutive months which will be analysed using a shared frailty model. Secondary outcomes are Health of the
Nation Outcome Scale (HoNOS), Process of Recovery Questionnaire (QPR), DIALOG (a service user-reported measure
of quality of life and treatment satisfaction) and service use outcomes which will be analysed using mixed effects
regression models.
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Discussion: This paper is the detailed statistical analysis plan for the EYE-2 trial. Any changes to, or deviations from,
this plan will be described and justified in the final trial report.
Trial registration: ISRCTN 51629746. Prospectively registered on 7 May 2019. Date assigned 10 May 2019.
Keywords: Psychosis, Early intervention, Engagement, Intervention, Cluster randomised trial, Statistical analysis plan
Background
Early Intervention in Psychosis (EIP) services improve
health outcomes for young people with severe mental ill-
ness in the medium-long term, but 25% of young people
disengage in the first 12 months at significant cost to
their mental health, their families, society and the Na-
tional Health Service (NHS). Our own feasibility-pilot
work clarified the issues that affect engagement. This
study will refine and test the team-based motivational
Early Youth Engagement (EYE-2) intervention to im-
prove engagement and outcomes for young people as
detailed in the published trial protocol paper [1]. The
statistical analysis plan (SAP) was written following
guidelines for SAPs by Gamble et al. [2].
Study objectives
To evaluate the effectiveness of the intervention with re-
spect to the primary outcome: time to disengagement
(in days from date of allocation to care coordinator to
date of the last contact following either refusal to engage
with EIP or lack of response to EIP contact for 3 con-
secutive months) and secondary, routinely collected and
researcher collected, outcomes (service use, deaths,
Health of the Nation Outcome Scale (HoNOS) [3],
Process of Recovery Questionnaire (QPR) [4], DIA-
LOG—a service-user-reported measure of quality of life
and treatment satisfaction [5]) derived from routine ser-
vice data at 0, 6, 12, 18 and 24 months.
Methods and design
Trial design
EYE-2 is a cluster randomised controlled trial to com-
pare the EYE-2 motivational engagement intervention
plus standardised EIP service to standardised EIP service
alone. Participating services are Early Intervention in
Psychosis (EIP) clinical teams (henceforth referred to as
teams) in 5 geographical locations in England including
East Anglia (4 teams), Hampshire (4 teams), Manchester
(5 teams), South London (3 teams) and Thames Valley
(4 teams). These teams aim to promote recovery and re-
duce treatment delay for people experiencing first epi-
sode psychosis (FEP) by providing early access to multi-
disciplinary support and treatment. Participating teams
were expected to have at least 35–60 new FEP cases per
year meeting participant inclusion criteria described
below. A cluster randomised design was chosen to
reduce the risk of contamination of the standardised EIP
service teams with the EYE-2 intervention which is a
team-based intervention. The intervention focuses on
engagement, and although largely delivered by care co-
ordinators (e.g. nurses, occupational therapists or social
workers), it is supported by all members of the team in-
cluding support workers, pharmacists, psychiatrists, psy-
chologists and employment specialists.
Inclusion criteria for service users were defined as fol-
lows: (1) consecutive referrals to EIP services during the
study recruitment period, (2) aged 14–35 years and (3)
meeting criteria for a FEP as determined by each local
service according to their own established criteria. Ex-
clusion criteria were (1) sub-threshold ‘at risk mental
state’, not meeting FEP criteria, (2) referrals over the age
of 35, (3) diagnostic uncertainty about psychosis at 12
months and (4) service exclusion criteria such as organic
or intoxication induced psychosis and specific
exclusions.
The EYE-2 intervention [1] is a novel team-based mo-
tivational engagement model delivered by EIP teams of
clinicians to young people with FEP. Key elements of the
approach are (1) transparent, open communication; (2)
social involvement and support from service users’ social
network; (3) collaborative approach supporting client
treatment choices; (4) hopeful supportive approach to-
wards meaningful goals; and (5) addressing personal bar-
riers to engagement. Clinicians delivering the approach
are provided with training and an implementation tool-
kit consisting of an implementation manual, individual
implementation checklists, online video resources and
training, myth-busting booklets on (i) mental health and
help-seeking, (ii) EIP services, (iii) advice for friends and
family and (iv) treatment choices, and an engagement-
focussed mental health companion website.
Blinding
Teams administering interventions and individual partic-
ipants are not blind to allocation. The research assistants
rating the primary outcome are blind to the allocation
status of teams at their respective sites. The statisticians,
health economists and process evaluation research team
members are also blind to allocation. The analysis will
be conducted using dummy labels for the trial arms,
using a code to which the statisticians are blinded. Final
unblinding will only occur once the statistical analysis
Jones et al. Trials          (2021) 22:732 Page 2 of 8
has been completed. SB had access to disaggregated data
by coded treatment allocation for the purposes of separ-
ate exploratory work relating to the COVID-19
pandemic.
Randomisation
A statistician at the Brighton and Sussex Clinical Trials
Unit generated a randomisation list comprising per-
muted blocks of size 2, stratified by site using a tool pro-
vided by Sealed Envelope™ [6], an independent online
randomisation service. To achieve statistician blinding
and to ensure concealment, this was sent to an inde-
pendent statistician to combine with the teams list, itself
randomly ordered within site by sorting a random num-
ber list and then uploaded to Sealed Envelope. The study
research fellow requested the password-protected con-
cealed allocations online once all the participating teams
at a site had reached the threshold for care coordinator
and staff recruitment (≥ 80%) and were deemed ready to
start.
Power and sample size
Participants are a consecutive sample in each service.
Time to disengagement will be analysed using frailty
analysis to adjust for clustering by team. Simulation con-
firms that 10 clusters (teams) per arm (N = 950 partici-
pants in total across the 20 teams) will achieve 90%
power to detect a difference corresponding to 12-month
disengagement rates of 25% (standard 12-month disen-
gagement rate from EIP service) [7–9] versus 15%, as-
suming time to disengagement follows an exponential
distribution; intracluster correlation coefficient of 0.05
(to be conservative in the absence of information on this
parameter); loss to follow-up rate 10% per year; conser-
vative significance level 3% to correct for inflation of
type I error due to the small number of teams; variable
cluster size modelled as a uniform random variable be-
tween 35 and 60; recruitment at referral; 12 months’ re-
cruitment plus 12 months’ follow-up. The target
reduction in disengagement and expected loss to follow-
up were based on data from the original EYE pilot pro-
ject. We did not anticipate any loss of teams during the
trial. Simulations were conducted using the SimSam
package in Stata 14 [10], see https://github.com/richard-
hooper/simsam/tree/EYE2.
In October 2019, the Trial Steering Committee asked
us to re-evaluate the statistical power in light of the
lower-than-expected rate of service user identification
and to consider an extended timetable for the trial. We
used recruitment figures to date to project the recruit-
ment to each team if we recruited for a total of 15.5
months, and calculated power assuming an additional
follow-up period of either 8.5 or 12 months. This re-
calculation of power was done blind to the actual
treatment allocations: simulations of power were con-
ducted over all possible randomisations of teams strati-
fied by site, with all other assumptions as in the original,
pre-trial power calculation above. We estimated the
power to be 85% with 15.5 months’ recruitment plus 8.5
months’ follow-up or 90% with 15.5 months’ recruitment
plus 12 months’ follow-up.
Statistical principles
Statistical software
Analyses will be performed in Stata version 16.1 or later
[11].
Confidence intervals and p values
Estimates of treatment effect, their 95% confidence inter-
vals and p values will be reported for comparisons be-
tween trial arms. The level of statistical significance is
5% (3% for the primary outcome).
Analysis population
Intention to treat principles will be followed to compare
outcomes of the participants in each intervention arm.
Loss to follow-up
Participants will be considered lost to follow-up if they:
 Moved to a mental health service outside the study
 Moved to a service in a different arm of the trial
 Moved to a mental health service in a different
country
 Died due to suicide
 Died due to other causes
 Asked to be withdrawn
 Withdrew for a safety reason
 Were discharged by mutual consent with no clinical
need
 Other reasons—which will be stated
Engagement status of participants who are lost to
follow-up will be censored at the time of their
withdrawal.
Participants whose eligibility has been confirmed but
their clinical team later revised their status as not FEP
will be considered post-identification exclusions due to
ineligibility and will not be included in the analysis. Par-
ticipants who are rated blindly as disengaged will be
followed up as per trial protocol.
Timing of outcome assessments
The primary outcome is assessed on a 6 monthly basis
by detailed case note review and trial database extracts,
and indication of potential disengagement/loss to
follow-up, by a research assistant blind to trial arm. Pri-
mary outcome status (engaged, disengaged, lost to
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follow-up) will be double-rated by an independent clin-
ician based on all available data, and any discrepancies
will be discussed to reach consensus. For those who have
disengaged or have been lost to follow-up, the timing of
this event will be retrospectively determined. For partici-
pants who remain engaged until the end of the study
follow-up period, time to disengagement is treated as
censored (unknown) beyond this point. This definition is
widely used in engagement research. People who engage
intermittently every few weeks or via text message or
phone would still be engaged. Engagement will be evalu-
ated according to the trial protocol and the EYE-2 Pri-
mary Outcome Rating Guidance Document (see
Additional file 1) by double-rating, by raters blind to the
allocation status of teams. Whilst final data entry and
cleaning is conducted, we will continue to follow up en-
gaged participants for a further 3 months to identify any
final disengagement outcomes.
Secondary outcomes will be measured at 0, 6 and 12
months for all participants, not necessarily with each
measure collected on the same date, and at 18 and 24
months for some, within an allowable window of −2 to
+4 weeks either side of the due date, except for baseline
for which the allowable window was −4 to +6 weeks and
included the possibility that some data may have been
collected whilst the participant was in an inpatient set-
ting. Where more than one baseline value is available,
we will select that which is closest to the date when the
patient was allocated to their care coordinator. Due to
the pressures of delivering clinical services, much of the
secondary outcome data is collected outside the allow-
able windows. In order to accommodate this, such ob-
servations will be snapped to the nearest interim
(pseudo) time point, i.e. 3, 9, 15 and 21 months.
Adherence and protocol deviations
Definition of adherence to the intervention and extent of
exposure
Adherence to the intervention will be measured at three
different time points during the trial using self-report
questionnaires administered to clinicians in each team
as part of the process evaluation. Clinicians’ self-
reported use of the key intervention resources ((i) EYE-2
booklets and (ii) website with service users and (iii) re-
ferrals of service users to social groups) will be used to
assess the extent of exposure. For each of the three tan-
gible components, clinicians rate the proportion of their
EYE-2 service users to whom they have provided the
intervention, rated on a 4-point Likert scale where 1 =
0–25% of my service users, 2 = 26–50% of my service
users, 3 = 51–75% of my service users and 4 = 76–100%
of my service users.
Presentation of adherence to the intervention
A composite mean adherence score will be calculated
for each clinician by averaging their individual scores in-
dicating the use of the three key intervention resources
listed above with service users, providing a mean com-
posite score ranging from 1 to 4. Summary statistics for
adherence to the intervention will be reported for the
intervention arm, and for each team, by averaging the
scores for all clinicians in each team who completed the
questionnaire at each of the three time points.
Protocol deviations
Data are collected at baseline and at 6 monthly regular
follow-up intervals. Data can be collected within −4 to
+6 weeks of baseline date (allocation to care coordin-
ator) and within −2 to +4 weeks of follow-up time
points. Data collected outside these periods will be
classed as out-of-window data collection deviations.
The proportion of data collected out-of-window will
be presented per trial arm for each time point for the
following measures: HoNOS, QPR and DIALOG.
Statistical analyses
Descriptive statistics
Participant progress through the study will be sum-
marised using a flow diagram according to the CON-
SORT extension for cluster randomised trials [12], as
presented in our trial protocol [1]. Screening data are
collected by the research assistant for each team. We
will report the number of patients screened, the number
deemed ineligible (patients who did not meet team in-
clusion criteria of a new FEP presentation aged 14–35,
at screening) with reasons and the number of eligible
participants as a proportion of those screened.
Participant loss to follow-up will be summarised over-
all and by intervention arm in a table.
The following baseline characteristics will be sum-




 Duration of untreated psychosis
 Level of educational attainment
 Deprivation score: Index of Multiple Deprivation
[13]
 Substance use score on HoNOS at baseline
 Symptom score on HoNOS at baseline
Statistics appropriate to the distribution of each vari-
able will be used, such as frequency and percentage for
categorical variables, mean and standard deviation for
normally distributed continuous variables or median and
interquartile range for skewed continuous variables.
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Interim analysis
No interim analysis was planned or conducted.
Outcome analyses
Primary outcome modelling: time to disengagement
Time to disengagement will be summarised by interven-
tion arm and compared between trial arms using Cox
regression with a gamma-distributed shared frailty to
allow for the clustering by team. Missing values for the
primary outcome, time to disengagement (due to loss to
follow-up or remaining engaged at the end of data col-
lection), are considered censored. The proportional haz-
ards assumption will be assessed using Schoenfeld
residuals. Should this assumption not be met, the model
will be fitted after splitting the follow-up at the median
(using Stata’s 'stsplit' command) and fitting the inter-
action between this and the randomisation variable. Al-
ternatively, if the assumption is not met due to one or
more covariates, we will stratify the modelling on these.
If this analysis fails to converge, we will employ fully
parametric time-to-event exponential regression analysis
with a shared frailty. With a relatively small number of
teams per arm, there is a risk that the type I error rate
will be inflated—we will use a permutation test in order
to obtain a true significance level [14]. Time to disen-
gagement or the time beyond which observations are
censored (due to loss to follow-up or end of data collec-
tion) will be known for all participants. Fixed effects will
include treatment allocation, site, age at allocation to
care coordinator and substance misuse score (HoNOS
question 3) at baseline. We will report the 2-sided p
value (and its 95% confidence interval) from the permu-
tation test of the treatment effect. We will also report
the estimated hazard ratio and its 95% confidence inter-
val from the shared frailty model specified above.
Secondary outcomes The following outcomes will be
summarised by intervention and time point (up to 24
months) arm. Outcomes to be modelled are indicated
with (m).
1. Service use
Service use data (primary endpoint 12 months), as ad-
vised by our GP commissioner, will include:
(i) Number of days spent in hospital (m)
(ii) Number of accident and emergency (A&E)
presentations (m)
(iii)Number of instances of Section 136 use (m)
2. Health of the Nation Outcome Scale (HoNOS)
The HoNOS [3] is the most widely employed routine
clinical outcome measure in the UK mental health
services. It is a 12-item clinician-rated scale which covers
a wide range of health and social outcomes including
mental health symptoms (psychosis, depression, others),
physical health, self-harm, substance use, cognition,
function (occupational and daily), relationships and
housing. Each item is rated from 0 (no problem) to 4
(very severe), for the preceding 2 weeks.
(i) Individual item scores
We will model the hallucinations/delusions (m)
item separately (question 6).
Subscale scores
(ii) Behavioural problems (questions 1–3, range 0 to
12) (m)
(iii) Impairment (questions 4 and 5, range 0 to 8) (m)
(iv) Symptoms (questions 6–8, range 0 to 12) (m)
(v) Social (questions 9-12, range 0 to 16) (m)
(vi)Overall score (sum of 12 questions, range 0 to 48)
(m)
3. Process of Recovery Questionnaire (QPR)
The QPR [4] is a 15-item measure, developed by psych-
osis service users to capture recovery. Items include so-
cial inclusion, assertiveness, motivation, positive
relationships, purpose, empowerment, self-esteem, self-
efficacy, meaningful activity, understanding, acceptance,
enjoyment and positive risk-taking, each rated on a 5-
point scale from 0, strongly disagree to 4, strongly agree.
The outcome is the total score for all 15 items.
(i) Overall score (sum of 15 questions, range 0 to 60)
(m)
4. DIALOG
The DIALOG [5] assesses patient-reported satisfaction
with 11 aspects of subjective quality of life including
health (mental and physical), function (work, leisure),
social (friendships/family relationships), accommodation,
personal safety and treatment (practical and mental
health support, medication) all rated on a 7-point scale
from 1, totally dissatisfied, to 7, totally satisfied. Scores
on the DIALOG are reported as two mean subscale
scores for Subjective Quality of life and Satisfaction with
treatment.
Subscale scores
(i) Subjective quality of life (mean of questions 1-8,
range 1 to 7) (m)
(ii) Treatment satisfaction (mean of questions 9-11,
range 1 to 7) (m)
5. Death
Death, including suicide, within 12 months of allocation
to care coordinator.
Jones et al. Trials          (2021) 22:732 Page 5 of 8
6. National Institute of Health and Care Excellence
(NICE) guideline interventions
Number of NICE guideline interventions within 12
months.
Secondary outcome modelling As not all participants
are followed up beyond 12 months, the greatest effort
has been focused on collecting data to 12 months; there-
fore, this is the data that will be used for the modelling.
HoNOS, QPR and DIALOG will be analysed using
mixed effects regression analysis of all non-missing data
(valid if outcomes are missing-at-random) appropriate to
distribution, with random effects for time point and for
team and a Kenward-Roger small-sample correction to
account for the small number of teams. From each
model, we will report the estimated treatment effect, its
95% CI and p value. If any of the models do not con-
verge, we will report a descriptive comparison of the
outcomes by trial group. Service use outcomes will be
modelled using mixed effects robust Poisson regression
with a random effect for team to account for clustering
at the team level, and the fixed effects listed below. We
will report the estimated incidence rate ratio for the
treatment effect and its 95% CI. Due to the small num-
ber of teams, a permutation test will be used to calculate
the p values.
Models will include the following fixed effects:
 Site
 Treatment allocation
 Outcome at baseline (HoNOS only)
 Age at allocation to care coordinator
 Time point
A substantial number of observations for HoNOS,
QPR and DIALOG fall outside the collection windows
for each time point. Observations for these outcomes
falling outside expected collection windows will be
quantified and visualised. Intermediate (pseudo) time
points at m3 and m9 will be created between the main
time points (m0, m6 and m12), and observations will be
assigned to the closest empty time point. For HoNOS,
baseline observations will not be reassigned to later time
points as data collection for HoNOS occurred close to
baseline, and baseline score will be included as a covari-
ate in the model. For QPR and DIALOG, baseline data
collection could occur after true baseline, so these obser-
vations may be reassigned to their closest empty time
point; otherwise, the baseline score will instead be in-
cluded in the outcome variable. An interaction between
treatment allocation and time will be included in these
models, but the treatment allocation (intervention) main
effect will not be included (QPR and DIALOG models),
as this represents a comparison of the outcome at
baseline. Omission of the treatment allocation main ef-
fect is equivalent to assuming equality of outcome be-
tween groups at baseline [15].
Missing data for secondary outcomes The specified
analysis of HoNOS, QPR and DIALOG is based in the
assumption that unobserved participants are missing-at-
random (MAR). For each of these outcomes, we will
examine the sensitivity of conclusions to this by imput-
ing outcome data departing from this assumption [16-
19]. This will be performed using Δ = Δoutcome + Y1P1
– Y0P0, where Δ is the treatment effect under MNAR,
Δoutcome is the treatment effect, estimated with the
‘margins’ command in Stata, from each secondary ana-
lysis model, Y11 and Y0 are the assumed mean partici-
pant responses of those missing data in the ‘EYE-2
intervention plus standardised EIP service’ and ‘standar-
dised EIP service alone’ arms respectively, and P1 and P0
are the proportions of participants excluded from ana-
lysis in their respective arms. Y0 will be varied for each
outcome variable, and for each value of Y0, Y1 will be set
equal to: {Y0 - x, Y0, Y0 + x}. The assumed mean re-
sponse (Y0) of participants missing data in the ‘standar-
dised EIP service alone’ arm will be varied across the
following values: HoNOS: {5, 10, 15, 20, 25, 30, 35, 40,
43}; QPR: {10, 20, 30, 40, 50}; and DIALOG: each sub-
scale {2, 3, 4, 5, 6}. The assumed mean response (Y1) of
participants missing data in the ‘EYE-2 intervention plus
standardised EIP service’ arm will be set equal to Y00 +
x for each x as follows: HoNOS: {-5, 0, 5}; QPR: {-10, 0,
10}; DIALOG: {-1, 0, 1}. We will calculate confidence in-
tervals for the treatment effect using the standard error
of Δoutcome, assumed approximately equal to the
standard error of Δ, from the complete case analysis. An
example of the application of this approach can be found
in Gillard et al. [20].
Additional analyses
Sensitivity analyses
 HoNOS, QPR and DIALOG models including only
observations collected in window.
 Method of data collection for HoNOS: We will
explore the impact of different methods of collection
of HoNOS, namely whether there are differences
between outcomes collected by care coordinators
and those collected by research assistants via case
notes screen (with/without checking by care
coordinator) or telephone interview with the
participant, by fitting a model which includes only
participants whose data were collected by their care
coordinator.
 Impact of the COVID-19 pandemic: We will use the
date of the first UK lockdown (16/3/21) and fit two
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models for each of disengagement, HoNOS, QPR
and DIALOG outcomes up to 12 months (1) includ-
ing only participants with baseline measure ascer-
tained before lockdown and (2) including only
participants with baseline data collected after lock-
down and pool the estimates from each pair of
models using a fixed-effects meta-analysis.
Subgroup analyses The primary analysis model will be
repeated on the following subgroups (in separate
models) by fitting an interaction term between the sub-
group variable at baseline and the treatment allocation
variable as follows:
 Substance misuse—binary 2, 3 or 4 vs. 0 or 1 on
HoNOS item 3
 Symptom severity (HoNOS symptom score)
 Ethnic group (mixed/other, any Black, any Asian vs.
any White)
 Educational attainment (degree, vocational, A-level,
GCSE vs. none)
 Deprivation category (high vs. low)
 Sex (male vs. female only)
Additionally for disengagement and HoNOS, QPR
and DIALOG, using the research assistant
questionnaire or EIP triangulation tool:
 Average caseload per care coordinator in the team
(high vs. low)
 Funding level per team (high vs. low)
Harms
Serious adverse events possibly, probably or definitely
related to the study intervention, will be summarised by
intervention arm and overall. This will include counts of
any events which resulted in death, were life-
threatening, required new or prolonged hospitalisation,
resulted in persistent or significant disability/incapacity,
or any other medically significant event.
Trial status
Follow-up for the trial finished on 6 July 2021 which is
12 months after the last participant was recruited. The
statistical analysis is anticipated to commence in Octo-
ber 2021 following a period of final data entry, data
cleaning and data lock.
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